

ASX Release
ASX Code: MEM

24 October 2024

Investor Webinar Invitation

Australian biotechnology company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to invite shareholders to attend an upcoming investor webinar to be held:

Time: 11am AEDT / 8am AWST
Date: 25th October 2024

Please follow the link to register:

<https://techinvest.online/techinvest-webinars/memphasys-limited-asx-mem-investor-webinar?hsLang=en>

The webinar will feature a presentation from Memphasys Managing Director and CEO Dr David Ali providing an update on the Company’s FelixTM System clinical trial progress which has reached 90% completion. The presentation will also detail Memphasys’ fast-tracked regulatory strategy which will see the Company target CE mark registration in Europe post-trial completion, offering a faster and more lucrative pathway than the Australian Therapeutic Goods Administration (TGA) registration.

Memphasys has also commenced a 3-year equine study which is anticipated to produce commercial outcomes within 12 months.

Following the formal presentation, investors have the opportunity to submit questions directly to management during a moderated Q&A session.

A recorded copy of the webinar will be made available following the event.

This announcement has been approved for release by the Board of Memphasys Limited.

ENDS

For further information, please contact:

Dr David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys



Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's patented bio separation technology, utilised by the Company's most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.